Market Research Logo

Diarrhea - Pipeline Review, H2 2015

Diarrhea - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Diarrhea - Pipeline Review, H2 2015’, provides an overview of the Diarrhea’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diarrhea and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Diarrhea
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Diarrhea and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Diarrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Diarrhea pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Diarrhea
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Diarrhea pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Diarrhea Overview
Therapeutics Development
Pipeline Products for Diarrhea - Overview
Pipeline Products for Diarrhea - Comparative Analysis
Diarrhea - Therapeutics under Development by Companies
Diarrhea - Therapeutics under Investigation by Universities/Institutes
Diarrhea - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Diarrhea - Products under Development by Companies
Diarrhea - Products under Investigation by Universities/Institutes
Diarrhea - Companies Involved in Therapeutics Development
A. Menarini Industrie Farmaceutiche Riunite Srl
Ache Laboratorios Farmaceuticos S/A
Actelion Ltd
Aegis Therapeutics, LLC
Akthelia pharmaceuticals ehf
Allergan Plc
Anatara Lifesciences Limited
Ardelyx, Inc.
Assembly Biosciences, Inc.
Chiesi Farmaceutici SpA
Chongqing Zhifei Biological Products Co., Ltd.
Cosmo Pharmaceuticals S.p.A
DesignMedix, Inc.
DiscoveryBiomed, Inc.
GlaxoSmithKline Plc
GP Pharm, S.A.
Helsinn Healthcare S.A.
Intercept Pharmaceuticals, Inc.
Ipsen S.A.
Merck & Co., Inc.
Mucosis B.V.
Nippon Shinyaku Co., Ltd.
Novartis AG
Pfizer Inc.
Prokarium Limited
Protagonist Therapeutics Inc.
Rebiotix Inc.
Sanofi Pasteur SA
Scandinavian Biopharma Holding AB
Shire Plc
Sigmoid Pharma Limited
Summit Therapeutics Plc
Synthetic Biologics, Inc.
Syntiron LLC
Diarrhea - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACE-527 - Drug Profile
ACE-920 - Drug Profile
ACH-04 - Drug Profile
AKT-10081 - Drug Profile
ASP-7147 - Drug Profile
cadazolid - Drug Profile
clostridium difficile vaccine - Drug Profile
crofelemer DR - Drug Profile
diarrhea vaccine - Drug Profile
diarrhea vaccine - Drug Profile
Drug for Diarrhea - Drug Profile
elsiglutide - Drug Profile
eluxadoline - Drug Profile
Escherichia coli vaccine - Drug Profile
ETEC vaccine - Drug Profile
Etvax - Drug Profile
fidaxomicin - Drug Profile
GVXNSD-133 - Drug Profile
Helicobacter pylori [Hel-305] (multivalent) vaccine - Drug Profile
ibodutant - Drug Profile
IMSUTMR-1501 - Drug Profile
infectious diarrhea [serotype H11] (H10407 and E24377A) vaccine - Drug Profile
iOWH0-32 - Drug Profile
lanreotide acetate - Drug Profile
MB-101 - Drug Profile
obeticholic acid - Drug Profile
octreotide acetate - Drug Profile
octreotide acetate MAR - Drug Profile
Peptide for Enterocolitis and Infectious Diarrhea - Drug Profile
PF-06425090 - Drug Profile
prulifloxacin - Drug Profile
PZ-7475 - Drug Profile
RBX-2660 - Drug Profile
RDX-009 - Drug Profile
Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea - Drug Profile
Recombinant Proteins for Infectious Diarrhea - Drug Profile
ridinilazole - Drug Profile
rifamycin - Drug Profile
Small Molecule for Diarrhea - Drug Profile
Small Molecule to Block CFTR for Diarrhoea - Drug Profile
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile
Small Molecules for Diarrhea - Drug Profile
Small Molecules for Microbial Infections - Drug Profile
Small Molecules to Inhibit CFTR for Secretory Diarrhea - Drug Profile
surotomycin - Drug Profile
SYN-004 - Drug Profile
Synthetic Peptide for Irritable Bowel Syndrome with Diarrhea - Drug Profile
Typhetec - Drug Profile
Vaccine for Campylobacter Caused Diarrhea - Drug Profile
Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea - Drug Profile
VP-20621 - Drug Profile
Yersinia pestis vaccine - Drug Profile
Diarrhea - Recent Pipeline Updates
Diarrhea - Dormant Projects
Diarrhea - Discontinued Products
Diarrhea - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Diarrhea, H2 2015
Number of Products under Development for Diarrhea - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015
Diarrhea - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015
Diarrhea - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2015
Diarrhea - Pipeline by Actelion Ltd, H2 2015
Diarrhea - Pipeline by Aegis Therapeutics, LLC, H2 2015
Diarrhea - Pipeline by Akthelia pharmaceuticals ehf, H2 2015
Diarrhea - Pipeline by Allergan Plc, H2 2015
Diarrhea - Pipeline by Anatara Lifesciences Limited, H2 2015
Diarrhea - Pipeline by Ardelyx, Inc., H2 2015
Diarrhea - Pipeline by Assembly Biosciences, Inc., H2 2015
Diarrhea - Pipeline by Chiesi Farmaceutici SpA, H2 2015
Diarrhea - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H2 2015
Diarrhea - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2015
Diarrhea - Pipeline by DesignMedix, Inc., H2 2015
Diarrhea - Pipeline by DiscoveryBiomed, Inc., H2 2015
Diarrhea - Pipeline by GlaxoSmithKline Plc, H2 2015
Diarrhea - Pipeline by GP Pharm, S.A., H2 2015
Diarrhea - Pipeline by Helsinn Healthcare S.A., H2 2015
Diarrhea - Pipeline by Intercept Pharmaceuticals, Inc., H2 2015
Diarrhea - Pipeline by Ipsen S.A., H2 2015
Diarrhea - Pipeline by Merck & Co., Inc., H2 2015
Diarrhea - Pipeline by Mucosis B.V., H2 2015
Diarrhea - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015
Diarrhea - Pipeline by Novartis AG, H2 2015
Diarrhea - Pipeline by Pfizer Inc., H2 2015
Diarrhea - Pipeline by Prokarium Limited, H2 2015
Diarrhea - Pipeline by Protagonist Therapeutics Inc., H2 2015
Diarrhea - Pipeline by Rebiotix Inc., H2 2015
Diarrhea - Pipeline by Sanofi Pasteur SA, H2 2015
Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H2 2015
Diarrhea - Pipeline by Shire Plc, H2 2015
Diarrhea - Pipeline by Sigmoid Pharma Limited, H2 2015
Diarrhea - Pipeline by Summit Therapeutics Plc, H2 2015
Diarrhea - Pipeline by Synthetic Biologics, Inc., H2 2015
Diarrhea - Pipeline by Syntiron LLC, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Diarrhea Therapeutics - Recent Pipeline Updates, H2 2015
Diarrhea - Dormant Projects, H2 2015
Diarrhea - Dormant Projects (Contd..1), H2 2015
Diarrhea - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Diarrhea, H2 2015
Number of Products under Development for Diarrhea - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report